Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

Webcast at 7:10 p.m. Eastern Time Today

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Analyses indicated a survival benefit in patients treated with OGX-011 in combination with docetaxel compared to docetaxel alone - the current standard care for patients with advanced prostate cancer:

    1)  The median overall survival in patients with advanced metastatic
        prostate cancer who were treated with OGX-011 plus docetaxel in a
        randomized Phase 2 trial was 23.8 months compared to 16.9 months for
        patients treated with docetaxel alone -- a 6.9 month observed
        survival advantage for the OGX-011 arm.

    2)  The unadjusted hazard ratio (HR), a measure used to compare the death
        rates between treatment groups, was 0.61, representing a 39% lower
        rate of death for patients treated with OGX-011.

    3)  A prospectively defined multivariate analysis indicated that the
        significant predictors of overall survival were treatment arm,
        performance status, and presence of metastases other than in bone or
        lymph nodes. Patients treated with OGX-011 had a rate of death 51%
        lower than patients treated with docetaxel alone (HR=0.49;
        p=0.012). Additional exploratory analyses found that the
        lower rate of death was associated with the effect of OGX-011
        treatment even when varying amounts of chemotherapy were administered
        (i.e. OGX-011 treatment resulted in a lower rate of death when
        compared to the control arm for patients receiving 6 or less cycles
        of chemotherapy as well as for patie
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in the fight against terrorism with the creation of ... with the use of light and special glass fibres. ... B: Chemical , the researchers describe a novel optical ... low as 6.3 ppm (parts per million). It requires ... "Traditionally explosives detection has involved looking for metals that ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... spiders can sit upside down forever. Nanophysics makes sure of ... an article just published in Physical Review E . ... and spiders that seem to be able to sit still ... for many years. We will soon be able to buy ... gecko,s foot. But the fact is, sooner or later the ...
(Date:7/10/2014)... The new alliance will see the two universities and ... working with business and industry and their complementary academic ... will help to shape the scientific priorities of the ... train up to 300 high-calibre PhD students, will provide ... at NPL, the potential of the Laboratory will be ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... , MALVERN, Pa. ... (AMR) and Decision Resources find that the leading driver ... broad-spectrum activity against gram-positive and gram-negative pathogens. Due to ... surveyed European physicians reveal that they look primarily for ...
... ... Top LASIK surgeons and recognized refractive and cataract surgery ... up-to-date on the latest developments in vision correction surgery, cataract surgery, ... Ophthalmology (AAO) annual meeting in San Francisco, California. Dr. Richard Lindstrom, ...
... VIENNA, Austria, November 19 AFFiRiS AG ... an unexpectedly early,stage of development: the vaccine candidate AD02 is ... This decision by the company,immediately follows the completion of two ... based its fast decision on the first interim,analysis of the ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... able to change their spots, but corals can change their ... chemical composition of the seawater around them. , That's the ... writing in the July issue of the journal Geology. ... is the first known case of an animal altering the ...
... born infected with human cytomegalovirus, or CMV, and about ... the virus ?almost one an hour. These disabilities can ... of coordination, and seizures. According to the Centers for ... cause of serious disability as Down syndrome, fetal alcohol ...
... Biologists from Washington University in St. Louis and their ... trees of rice varieties and have determined that the ... Asian locales. , Jason Londo, Washington University in Arts ... A. Schaal, Ph.D., Washington University Spencer T. Olin Professor ...
Cached Biology News:Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Innovative method for creating a human cytomegalovirus vaccine outlined 2Biologists find regions of rice domestication 2